Heart and Vessels

, Volume 34, Issue 10, pp 1600–1607 | Cite as

Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

  • Yipin ZhaoEmail author
  • Jiaojiao Yang
  • Yingying Ji
  • Shunli Wang
  • Tong Wang
  • Fengyun Wang
  • Jianmin TangEmail author
Original Article


No-reflow is one of the major complications of primary percutaneous coronary artery intervention (pPCI) in the treatment of acute ST-segment elevation myocardial infarction (STEMI). Fibrinogen-to-albumin ratio (FAR) has currently emerged as a novel inflammatory marker to predict inflammation in chronic diseases. This study aimed to investigate whether admission FAR values predicts angiographic no-reflow and short-term prognosis in all STEMI patients. A total of 510 consecutive STEMI patients who underwent successful pPCI between September 2016 and May 2018 were included in this study. Patients were divided into groups based on thrombolysis in myocardial infarction (TIMI) flow grades after pPCI. No-reflow was defined as a post-PCI TIMI flow grade of 0, 1, or 2. Angiographic success was defined as TIMI flow grade 3. Fibrinogen, hs-CRP, and admission FAR values were significantly higher among patients with no-reflow. On multivariate analysis, admission FAR was an independent predictor of angiographic no-reflow (p < 0.001). Receiver-operating characteristics analysis revealed the cut-off value of admission FAR was a predictor of no-reflow with a sensitivity of 79.59% and a specificity of 69.42%. In multivariable Cox regression models adjusted for potential confounders, admission FAR values, and LVEF, hs-CRP was independently and positively associated with the 30-day all-cause mortality. Admission FAR was associated independently and significantly with angiographic no-reflow and short-term mortality in patients with STEMI undergoing pPCI.


ST-segment elevation myocardial infarction Thrombus grade Primary percutaneous coronary intervention Fibrinogen-to-albumin ratio 


Compliance with ethical standards

Conflicts of interest

There are no conflicts of interest.


  1. 1.
    O’Gara PT, Kushner FG, Ascheim DD, Casey DJ, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127:e362–e425Google Scholar
  2. 2.
    Jaffe R, Charron T, Puley G, Dick A, Strauss BH (2008) Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 117:3152–3156CrossRefGoogle Scholar
  3. 3.
    Galasso G, Schiekofer S, D’Anna C, Gioia GD, Piccolo R, Niglio T, Rosa RD, Strisciuglio T, Cirillo P, Piscione F, Trimarco B (2014) No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. Angiology 65:180–189CrossRefGoogle Scholar
  4. 4.
    Schwartz BG, Kloner RA (2012) Coronary no reflow. J Mol Cell Cardiol 52:873–882CrossRefGoogle Scholar
  5. 5.
    Celik T, Iyisoy A, Yuksel UC, Jata B, Ozkan M (2009) The impact of admission C-reactive protein levels on the development of no-reflow phenomenon after primary PCI in patients with acute myocardial infarction: the role of inflammation. Int J Cardiol 86–88Google Scholar
  6. 6.
    Kurtul A, Yarlioglues M, Celik IE, Duran M, Elcik D, Kilic A, Oksuz F, Murat SN (2015) Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis 26:706–712CrossRefGoogle Scholar
  7. 7.
    Niccoli G, Burzotta F, Galiuto L, Crea F (2009) Myocardial no-reflow in humans. J Am Coll Cardiol 54:281–292CrossRefGoogle Scholar
  8. 8.
    Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio A, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119–177CrossRefGoogle Scholar
  9. 9.
    Durante A, Camici PG (2015) Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol 187:273–280CrossRefGoogle Scholar
  10. 10.
    Jaffe R, Charron T, Puley G, Dick A, Strauss BH (2008) Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 117:3152–3156CrossRefGoogle Scholar
  11. 11.
    Rezkalla SH, Kloner RA (2008) Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 72:950–957CrossRefGoogle Scholar
  12. 12.
    Celik T, Balta S, Ozturk C, Kaya MG, Aparci M, Yildirim OA, Demir M, Unlu M, Demirkol S, Kilic S, Iyisoy A (2015) Predictors of no-reflow phenomenon in young patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology 67:683–689CrossRefGoogle Scholar
  13. 13.
    Kurtul A, Murat SN, Yarlioglues M, Duran M, Celik IE, Kilic A (2015) Mild to moderate renal impairment is associated with no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. Angiology 66:644–651CrossRefGoogle Scholar
  14. 14.
    Akpek M, Kaya MG, Lam YY, Sahin O, Elcik D, Celik T, Ergin A, Gibson CM (2012) Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 110:621–627CrossRefGoogle Scholar
  15. 15.
    Oduncu V, Tanalp AC, Erkol A, Sirma D, Dundar C, Akgun T, Turkyilmaz E, Kilicgedik A, Gozubuyuk G, Tigen K, Izgi A, Kirma C (2011) Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty. Am J Cardiol 107:179–185CrossRefGoogle Scholar
  16. 16.
    Nicholson JP, Wolmarans MR, Park GR (2000) The role of albumin in critical illness. Br J Anaesth 85:599–610CrossRefGoogle Scholar
  17. 17.
    Quinlan GJ, Martin GS, Evans TW (2005) Albumin: biochemical properties and therapeutic potential. Hepatology 41:1211–1219CrossRefGoogle Scholar
  18. 18.
    Chojkier M (2005) Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J Clin Gastroenterol 39:S143–S146CrossRefGoogle Scholar
  19. 19.
    Gresele P, Deckmyn H, Huybrechts E, Vermylen J (1984) Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochem Pharmacol 33:2083–2088CrossRefGoogle Scholar
  20. 20.
    Gonzalez-Pacheco H, Amezcua-Guerra LM, Sandoval J, Martinez-Sanchez C, Ortiz-Leon XA, Pena-Cabral MA, Bojalil R (2017) Prognostic implications of serum albumin levels in patients with acute coronary syndromes. Am J Cardiol 119:951–958CrossRefGoogle Scholar
  21. 21.
    Kurtul A, Murat SN, Yarlioglues M, Duran M, Ocek AH, Koseoglu C, Celik IE, Kilic A, Aksoy O (2016) Usefulness of SYNTAX Score and in-hospital mortality in patients with acute coronary syndrome. Angiology 67:34–40CrossRefGoogle Scholar
  22. 22.
    Nguyen XM, Lane J, Smith BR, Nguyen NT (2009) Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. J Gastrointest Surg 13:1205–1212CrossRefGoogle Scholar
  23. 23.
    Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK (2001) Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 21:611–617CrossRefGoogle Scholar
  24. 24.
    Gao XY, Zhou BY, Zhang MZ, Zhao X, Qing P, Zhu CG, Wu NQ, Guo YL, Gao Y, Li XL, Wang Y, Liu G, Dong Q, Guo LH, Li JJ (2017) Association between fibrinogen level and the severity of coronary stenosis in 418 male patients with myocardial infarction younger than 35 years old. Oncotarget 8:81361–81368Google Scholar
  25. 25.
    Kurtul A, Yarlioglues M, Murat SN, Duran M, Oksuz F, Koseoglu C, Celik IE, Kilic A, Aksoy O (2016) The association of plasma fibrinogen with the extent and complexity of coronary lesions in patients with acute coronary syndrome. Kardiol Pol 74:338–345Google Scholar
  26. 26.
    Karahan O, Acet H, Ertas F, Tezcan O, Caliskan A, Demir M, Kaya AF, Demirtas S, Cevik MU, Yavuz C (2016) The relationship between fibrinogen to albumin ratio and severity of coronary artery disease in patients with STEMI. Am J Emerg Med 34:1037–1042CrossRefGoogle Scholar
  27. 27.
    Karahan O, Yavuz C, Kankilic N, Demirtas S, Tezcan O, Caliskan A, Mavitas B (2016) Simple blood tests as predictive markers of disease severity and clinical condition in patients with venous insufficiency. Blood Coagul Fibrinol 27:684–690CrossRefGoogle Scholar
  28. 28.
    Yang WM, Zhang WH, Ying HQ, Xu YM, Zhang J, Min QH, Huang B, Lin J, Chen JJ, Wang XZ (2018) Two new inflammatory markers associated with disease activity score-28 in patients with rheumatoid arthritis: albumin to fibrinogen ratio and C-reactive protein to albumin ratio. Int Immunopharmacol 62:293–298CrossRefGoogle Scholar
  29. 29.
    Tan Z, Zhang M, Han Q, Wen J, Luo K, Lin P, Zhang L, Yang H, Fu J (2017) A novel blood tool of cancer prognosis in esophageal squamous cell carcinoma: the fibrinogen/albumin ratio. J Cancer 8:1025–1029CrossRefGoogle Scholar
  30. 30.
    Li SQ, Jiang YH, Lin J, Zhang J, Sun F, Gao QF, Zhang L, Chen QG, Wang XZ, Ying HQ (2018) Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals. Cancer Med 7(4):1221–1231CrossRefGoogle Scholar
  31. 31.
    Hwang KT, Chung JK, Roh EY, Kim J, Oh S, Kim YA, Rhu J, Kim S (2017) Prognostic influence of preoperative fibrinogen to albumin ratio for breast cancer. J Breast Cancer 20:254–263CrossRefGoogle Scholar
  32. 32.
    Xu Q, Yan Y, Gu S, Mao K, Zhang J, Huang P, Zhou Z, Chen Z, Zheng S, Liang J, Lin Z, Wang J, Yan J, Xiao Z (2018) A Novel Inflammation-Based Prognostic Score: the fibrinogen/albumin ratio predicts prognoses of patients after curative resection for hepatocellular carcinoma. J Immunol Res 2018:4925498Google Scholar
  33. 33.
    de Sain-van der Velden MGM, Smolders HC, van Rijn HJM, Voorbij HAM (2000) Does albumin play a role in fibrinolysis by its inhibition of plasminogen activation? Fibrinolysis Proteolysis 14(4):242–246CrossRefGoogle Scholar
  34. 34.
    Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R (2013) Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 58:1836–1846CrossRefGoogle Scholar
  35. 35.
    Albert MA, Glynn RJ, Buring JE, Ridker PM (2007) Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease. Am J Cardiol 99:1246–1251CrossRefGoogle Scholar
  36. 36.
    Guo YH, Hernandez I, Isermann B, Kang TB, Medved L, Sood R, Kerschen EJ, Holyst T, Mosesson MW, Weiler H (2009) Caveolin-1-dependent apoptosis induced by fibrin degradation products. Blood 113:4431–4439CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of CardiologyThe Second Affiliated Hospital of Zhengzhou UniversityZhengzhouPeople’s Republic of China
  2. 2.Department of GastroenterologyThe Second Affiliated Hospital of Zhengzhou UniversityZhengzhouPeople’s Republic of China

Personalised recommendations